Pay in 4 interest-free payments of $7.31 Learn more
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15
doi: 10.1016/j.jacc.2020.02.056 258 KernanWNViscoliCMFurieKLYoungLHInzucchiSEGormanMet al
Body weight and fasting glucose levels were unchanged (Supplemental Figure 1, A and B
Animal studies have shown concerns like reduced fetal growth, developmental abnormalities, and pregnancy loss at doses similar to those used in humans
Pharmaceutical companies are already racing to develop: next-generation GLP-1 drugs oral GLP-1 formulations dual- and triple-agonist metabolic therapies combination treatments targeting obesity and metabolic syndrome For sponsors, the commercial stakes are enormous
US$ 26.08
US$ 21.99
US$ 27.77
US$ 28.05
US$ 28.00
